Critical evaluation of the plasma concentration variation of B-type natriuretic peptide in emergency in paroxysmal atrial fibrillation, in acute pulmonary embolism, in acute coronary syndrome and in dilated cardiomyopathy;Variazioni della concentrazione plasmatica del peptide natriuretico di tipo B in urgenza nella fibrillazione atriale parossistica, nell'edema polmonare acuto, nella sindrome coronarica acuta e nella cardiomiopatia dilatativa

Annali Italiani di Medicina Interna

Volumn 20, Issue 3, 2005, Pages 167-186

  Coppola, Alessandro ^a   De Paola, Gaetano ^a   Suppa, Marianna ^a   Maggi, Barbara ^a   Giancaspro, Giuseppe ^a   Colzi, Marina ^a   Arcieri, Andrea ^a   Scarpellini, Gabriella ^a   Manetti, Elisa ^a   Acerna, Luciana ^a   Gerratano, Giuseppina ^a   Santulli, Maria ^a   Aguglia, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute coronary syndrome; Acute pulmonary edema; B type natriuretic peptide; Heart failure; Neuroendocrine systems; Paroxysmal atrial fibrillation

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY ATHEROSCLEROSIS; DIFFERENTIAL DIAGNOSIS; EMERGENCY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; DIAGNOSIS, DIFFERENTIAL; EMERGENCIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PULMONARY EMBOLISM; SENSITIVITY AND SPECIFICITY;

EID: 33644619228     PISSN: 03939340     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Sudoh T, Minamino N, Kangawa K, Matsuo H. Brain natriuretic peptide-32: N-terminal six amino-acid extended form of brain natriuretic peptide identified in porcine brain. Biochem Biophys Res Commun 1988; 155: 726-32.
2. Hosoda K, Nakao K, Mukoyama M, et al. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension 1991; 17: 1152-5.
3. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med 1999; 134: 437-44.
4. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
5. Levin ER, Gardner DG, Samson WK. Mechanisms of disease: natriuretic peptides. N Engl J Med 1998; 339: 321-8.
6. De Lemos JA, McGuire DK, Drazner HH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-22.
7. Maisel AS, McCullough PA. Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. Rev Cardiovasc Med 2003; 4 (Suppl 4): S3-S12.
8. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003; 4: 72-80.
9. Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care 2004; 10: 336-41.
10. Vanderheyden H, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004; 6: 261-8.
11. Koller KJ, Goedder DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992; 86: 1081-8.
12. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci 2005; 108: 23-6.
13. Cowie MR, Jourdain P, Maisel AS, et al. Clinical application of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710-8.
14. Remme WJ, Swedberg K, for the Task force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
15. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-54.
16. Maisel AS, Krishnaswamy P, Nowak RM, et al, for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 350: 347-54.
17. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379-85.
18. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multi-national Study. Circulation 2002; 106: 416-22.
19. Davis M, Espiner EA, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343: 440-4.
20. Ailani RK, Ravakhah K, Di Giovine B, et al. Dyspnea differentiation index: a new method for the rapid separation of cardiac vs pulmonary dyspnea. Chest 1999; 116: 1100-4.
21. Maisel AS, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004; 44: 1328-33.
22. Teboul A, Gaffinel A, Meune C, Griffet A, Sauval P, Carli P. Management of acute dyspnoea: use and feasibility of brain natriuretic peptide (BNP) assay in the pre-hospital setting. Resuscitation 2004; 61: 91-6.
23. Morimoto T, Hayashino Y, Shimbo T, Izumi T, Fukui T. Is the B-type natriuretic peptide-guided heart failure management cost-effective? Int J Cardiol 2004; 96: 177-81.
24. Mark DB, Felker GM. B-type natriuretic peptide. A biomarker for all seasons? N Engl J Med 2004; 350: 718-20.
25. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41:113-20.
26. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA. Value of natriuretic peptide in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.
27. McClure SJ, Caruana L, Davie AP, Goldthorp S, McMurray JJ. Cohort study of plasma natriuretic peptide for identifying left ventricular systolic dysfunction in primary care. BMJ 1998; 317: 516-9.
28. Hobbs R. Can heart failure be diagnosed in primary care? BMJ 2000; 321: 188-9.
29. Wieczorek SJ, Wu AH, Christenson RH, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002; 144: 834-9.
30. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA 2002; 288: 1252-9.
31. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-63.
32. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38: 1934-41.
33. Yamaguchi H, Yoshida J, Yamamoto K, et al. Elevation of plasma brain natriuretic peptide in a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 55-60.
34. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-7.
35. Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 292-9.
36. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic values of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
37. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptide and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107: 2786-92.
38. Takase H, Toriyama T, Sugiura T, Ueda R, Dohi Y. Brain natriuretic peptide in prediction of recurrence of angina pectoris. Eur J Clin Invest 2004; 34: 79-84.
39. Omland T, Richards AM, Wergeland R, Vik-Mo H. B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol 2005; 95: 24-8.
40. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Preliminary evaluation of the AxSYM B-type natriuretic peptide (BNP) assay and comparison with the ADVIA Centaur BNP assay. Clin Chem 2004; 50: 1104-6.
41. Landray MJ, Lehman R, Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study. BMJ 2000; 320: 985-6.
42. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315-21.
43. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004; 109: 3176-81.
44. Schaufelberger M, Bergh CH, Caidahl K, et al. Can brain natriuretic peptide (BNP) be used as a screening tool in general practice? Scand J Prim Health Care 2004; 22: 187-90.
45. Scardi S, Mazzone C. Fibrillazione atriale e scompenso cardiaco: causa o effetto? Ital Heart J Suppl 2002; 3: 899-907.
46. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide (BNP) in elucidating left ventricular dysfunction (systolic and diastolic) in patients with and without symptoms of congestive heart failure at a veteran's hospital. Am J Med 2001; 111: 274-9.
47. Stewart RA. Broader indication for B-type natriuretic peptide testing in coronary artery disease. Eur Heart J 2005; 26: 207-9.
48. Bassan R, Potsch A, Maisel AS, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur Heart J 2005; 26: 234-40.
49. Leroy G, Uzan L, Bugugnani MJ, et al. The value of repeated determinations of brain natriuretic peptide for the diagnosis of unstable angina. Arch Mal Coeur Vaiss 2003; 96: 305-10.
50. Nishikimi T, Matsuoka H. Plasma brain natriuretic peptide levels indicate the distance from decompensated heart failure. Circulation 2004; 109: E329-E330.
51. Van Gelder IC, Crijns HJ, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993; 72: 560-6.
52. Richards AM, Lainchbury LG, Troughton RW, Nicholls MG, Frampton CM, Yandle TG. Plasma amino-terminal pro-B-type natriuretic peptide predicts post-cardioversion reversion to atrial fibrillation [abstract]. Am J Cardiol 2003; 41 (Suppl A): 99A.
53. Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002; 39: 1623-9.
54. Cheng V, Kazanegra R, Gracia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386-91.
55. Bettencourt P, Ferreira S, Azevedo A, Ferreira A. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcomes after hospital discharge in patients with heart failure. Am J Med 2002; 113: 215-9.
56. Maisel AS. Algorithms for using B-type natriuretic peptide levels in the diagnosis and management of congestive heart failure. Critical Pathways in Cardiology 2002; 1: 67-73.
57. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission for decompensated heart failure. J Am Coll Cardiol 2004; 43: 635-41.
58. Nagaya N, Nishikimi T, Goto Y, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998; 135: 21-8.
59. Palazzuoli A, Calabria P, Vecchiato L, et al. Plasma brain natriuretic peptide levels in coronary heart disease with preserved systolic function. Clin Exp Med 2004; 4: 44-9.
60. Richards AM, Nicholls MG, Yandle TG, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart 1999; 81: 114-20.
61. Silver MA, Maisel AS, Yancy CW, et al. BNP Consensus Panel 2004. A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular disease. Congest Heart Fail 2004; 10 (Suppl 3): 1-30.
62. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
63. National Institute for Clinical Excellence. Clinical guidelines 5. Chronic heart failure in adults in primary and secondary care. London, 2003: 1-44.
64. Scardovi AB; Associazione Nazionale Medici Cardiologi Ospedalieri; Società Italiana di Cardiologia Pediatrica; Società Italiana di Nefrologia Pediatrica; Società Italiana dell'Ipertensione Arteriosa; Società Italiana di Pediatria. Impiego clinico del dosaggio del peptide natriuretico di tipo B. Ital Heart J Suppl 2004; 5: 343-56.